Image

Pulmonary Vein Isolation (PVI) Combined With Renal Denervation (RDN) in Atrial Fibrillation (AF) and Hypertension (HTN)

Pulmonary Vein Isolation (PVI) Combined With Renal Denervation (RDN) in Atrial Fibrillation (AF) and Hypertension (HTN)

Recruiting
18-75 years
All
Phase N/A

Powered by AI

Overview

The close relationship between the increase of sympathetic tension, AF, and HTN cannot be ignored. In addition, the significant failure rate of PVI (20-50%) in the treatment of AF makes it very necessary to explore the effect of RDN on AF. Therefore, this study aims to compare the effects and safety of PVI alone and PVI combined with RDN with AF combined with HTN, which will open a new chapter for PVI combined with RDN in the treatment of AF.

Eligibility

Inclusion Criteria:

  • 18<age<75years
  • clinic blood pressure≥140/90mmHg or 24-hour ambulatory blood pressure monitoring average blood pressure ≥135/85mmHg
  • Ecg diagnosis of atrial fibrillation ;
  • who signed informed consent and were approved by the Ethics Committee of the First Affiliated Hospital of Xiamen University.

Exclusion Criteria:

  • pregnant women or lactating patients;
  • Patients who were unsuitable for ablation before surgery (unilateral or bilateral renal artery shape and structure were found: renal artery stenosis exceeding 50%, renal aneurysm, previous renal artery interventional surgery, renal artery malformation, renal artery diameter < 4mm or length of treatable segment < 20mm)
  • Patients who only have one kidney or have a history of kidney transplantation
  • Patients with a history of renal arterial intervention or renal denervation
  • identified secondary hypertension or Pseudo hypertension except for renal parenchymal hypertension;
  • malignant tumors or end-stage diseases;
  • Severe peripheral vascular disease, abdominal aortic aneurysm
  • whose left atrium is larger than 55mm
  • obvious bleeding tendency and blood system diseases;
  • Severe peripheral vascular disease, abdominal aortic aneurysm;
  • A history of the acute coronary syndrome within two weeks;
  • acute or severe systemic infection;
  • drug or alcohol dependence or refusal to sign informed consent.
  • Other conditions that are not suitable for PVI and RDN

Study details
    AF - Atrial Fibrillation
    HTN-Hypertension

NCT05841615

The First Affiliated Hospital of Xiamen University

19 March 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.